ATE455555T1 - Glp-1-analoga - Google Patents

Glp-1-analoga

Info

Publication number: ATE455555T1
Authority: AT; Austria
Prior art keywords: glp; analogue
Prior art date: 2003-02-19

Application number

AT04711811T

Other languages

English (en)

Inventor

Zheng Dong

Original Assignee

Ipsen Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-19

Filing date

2004-02-17

Publication date

2010-02-15

2004-02-17 Application filed by Ipsen Pharma filed Critical Ipsen Pharma

2010-02-15 Application granted granted Critical

2010-02-15 Publication of ATE455555T1 publication Critical patent/ATE455555T1/de

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)

AT04711811T 2003-02-19 2004-02-17 Glp-1-analoga ATE455555T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44920303P	2003-02-19	2003-02-19
PCT/US2004/004421 WO2004074315A2 (en)	2003-02-19	2004-02-17	Analogues of glp-1

Publications (1)

Publication Number	Publication Date
ATE455555T1 true ATE455555T1 (de)	2010-02-15

Family

ID=32908694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04711811T ATE455555T1 (de)	2003-02-19	2004-02-17	Glp-1-analoga

Country Status (11)

Country	Link
US (1)	US20060217300A1 (de)
EP (2)	EP2067483A1 (de)
JP (1)	JP2007524579A (de)
CN (2)	CN1750842A (de)
AR (1)	AR043365A1 (de)
AT (1)	ATE455555T1 (de)
CA (1)	CA2513307A1 (de)
DE (1)	DE602004025205D1 (de)
ES (1)	ES2336563T3 (de)
TW (1)	TWI283684B (de)
WO (1)	WO2004074315A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1750842A (zh)	2003-02-19	2006-03-22	研究及应用科学协会股份有限公司	Glp－1的类似物
JP2007537981A (ja) *	2003-09-19	2007-12-27	ノボ　ノルディスク　アクティーゼルスカブ	新規の血漿タンパク質親和性タグ
CA2551039C (en)	2003-12-16	2013-01-29	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Analogues of glp-1
BRPI0608516A2 (pt)	2005-03-18	2010-11-16	Novo Nordisk As	análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
TWI372629B (en)	2005-03-18	2012-09-21	Novo Nordisk As	Acylated glp-1 compounds
JP5096363B2 (ja)	2005-12-16	2012-12-12	ネクターセラピューティックス	Ｇｌｐ−１のポリマ複合体
MX2008013304A (es)	2006-04-20	2008-10-27	Amgen Inc	Compuestos de peptido 1 tipo glucagon.
GB2448895A (en) *	2007-05-01	2008-11-05	Activotec Spp Ltd	GLP-1 like compounds and uses thereof
BRPI0915282A2 (pt) *	2008-06-17	2017-02-07	Univ Indiana Res & Tech Corp	agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
MX2011000847A (es)	2008-08-06	2011-02-25	Novo Nordisk Healthcare Ag	Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es)	2009-01-22	2011-09-06	Novo Nordisk Healthcare Ag	Compuestos de hormona del crecimiento estables.
CN102414220A (zh) *	2009-05-01	2012-04-11	霍夫曼-拉罗奇有限公司	使用固相和液相组合技术的促胰岛素肽合成
WO2011015649A1 (en)	2009-08-06	2011-02-10	Novo Nordisk Health Care Ag	Growth hormones with prolonged in-vivo efficacy
CN118767117A (zh)	2010-01-22	2024-10-15	诺沃—诺迪斯克保健股份有限公司	体内功效延长的生长激素
BR112012018162A2 (pt)	2010-01-22	2017-10-03	Novo Nordisk Healthcare Ag	Compostos de hormônio do crescimento estáveis
WO2012054822A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Glp-1 polymer conjugates having a releasable linkage
TWI588153B (zh)	2012-05-18	2017-06-21	中國醫藥大學	多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
CN105120887A (zh)	2013-04-05	2015-12-02	诺和诺德保健股份有限公司	生长激素化合物制剂
PL3393496T3 (pl)	2015-12-23	2024-04-22	The Johns Hopkins University	Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
TWI799680B (zh) *	2019-01-29	2023-04-21	美商美國禮來大藥廠	製備gip/glp1雙重促效劑之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1539498A (en)		1925-05-26		And fifteen
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
WO1999043706A1 (en) *	1998-02-27	1999-09-02	Novo Nordisk A/S	Derivatives of glp-1 analogs
FR2777283B1 (fr) *	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6720407B1 (en) *	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
PL205713B1 (pl) *	1998-12-07	2010-05-31	Sod Conseils Rech Applic	Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CN1495198A (zh) *	1998-12-07	2004-05-12	�о��Ӧ�ÿ�ѧЭ��ɷ��޹�˾	胰高血糖素样肽-1的类似物
EP1239871A1 (de) *	1999-11-12	2002-09-18	Novo Nordisk A/S	Verwendung von glp-1-agonisten zur hemmung der degeneration von beta-zellen
US6844321B2 (en) *	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
AU6479101A (en) *	2000-06-16	2002-01-02	Lilly Co Eli	Glucagon-like peptide-1 analogs
CN1750842A (zh)	2003-02-19	2006-03-22	研究及应用科学协会股份有限公司	Glp－1的类似物
CN114612953B (zh)	2020-12-09	2025-09-26	佳能株式会社	对象识别模型的训练方法及装置

2004
- 2004-02-17 CN CNA2004800046584A patent/CN1750842A/zh active Pending
- 2004-02-17 US US10/546,303 patent/US20060217300A1/en not_active Abandoned
- 2004-02-17 ES ES04711811T patent/ES2336563T3/es not_active Expired - Lifetime
- 2004-02-17 CA CA002513307A patent/CA2513307A1/en not_active Abandoned
- 2004-02-17 CN CN2010102818115A patent/CN101942018A/zh active Pending
- 2004-02-17 AT AT04711811T patent/ATE455555T1/de not_active IP Right Cessation
- 2004-02-17 WO PCT/US2004/004421 patent/WO2004074315A2/en not_active Ceased
- 2004-02-17 EP EP09156363A patent/EP2067483A1/de not_active Withdrawn
- 2004-02-17 DE DE602004025205T patent/DE602004025205D1/de not_active Expired - Lifetime
- 2004-02-17 JP JP2006503594A patent/JP2007524579A/ja active Pending
- 2004-02-17 EP EP04711811A patent/EP1594529B1/de not_active Expired - Lifetime
- 2004-02-19 TW TW093104154A patent/TWI283684B/zh active
- 2004-02-19 AR ARP040100518A patent/AR043365A1/es unknown

Also Published As

Publication number	Publication date
EP1594529A4 (de)	2008-01-16
US20060217300A1 (en)	2006-09-28
HK1083762A1 (en)	2006-07-14
CN101942018A (zh)	2011-01-12
WO2004074315A2 (en)	2004-09-02
EP1594529A2 (de)	2005-11-16
TW200418877A (en)	2004-10-01
JP2007524579A (ja)	2007-08-30
ES2336563T3 (es)	2010-04-14
EP1594529B1 (de)	2010-01-20
DE602004025205D1 (de)	2010-03-11
CA2513307A1 (en)	2004-09-02
AR043365A1 (es)	2005-07-27
TWI283684B (en)	2007-07-11
WO2004074315A3 (en)	2004-11-25
EP2067483A1 (de)	2009-06-10
CN1750842A (zh)	2006-03-22

Legal Events

Date	Code	Title	Description
2010-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
SI1641823T1 (sl)	2011-12-30	Fuzijski proteini analogni glp-1
DE602004031845D1 (de)	2011-04-28	Ng
ATE457980T1 (de)	2010-03-15	Aryloxime
ATE534648T1 (de)	2011-12-15	C-6-modifizierte indazolylpyrrolotriazine
ATE427876T1 (de)	2009-04-15	Luftkissenboot
ATE318817T1 (de)	2006-03-15	Aza-arylpiperazine
DE50212360D1 (de)	2008-07-24	Anfahrhilfesteuerungsvorrichtung
DE50212349D1 (de)	2008-07-17	Hirurgie
ATE455555T1 (de)	2010-02-15	Glp-1-analoga
DE50301200D1 (de)	2005-10-20	Wischblatt
SE0302091L (sv)	2005-03-08	Genomföring
ATE349458T1 (de)	2007-01-15	Etonogestrelester
DK1492934T3 (da)	2010-10-04	Dørenhed
FI20031679L (fi)	2005-05-20	Työnnin
DE50301960D1 (de)	2006-01-26	Hydrolager
PT1678290T (pt)	2017-10-16	Resumo
DE602004018799D1 (de)	2009-02-12	Ng
ATA4142004A (de)	2005-12-15	Trägerverbau
ATE469773T1 (de)	2010-06-15	Zugöse
ATA19152002A (de)	2004-11-15	Hubkupplung
DE50209283D1 (de)	2007-03-08	Tropfbewässerungsrohr
ATE396192T1 (de)	2008-06-15	N-sulfonylaminothiazole
FI20020915A0 (fi)	2002-05-15	Viira
DE10244834B8 (de)	2005-01-13	Suszeptometer
DE50300322D1 (de)	2005-03-31	Zylinderkopfdichtung